Moleculin Biotech (NASDAQ:MBRX) Upgraded to “Buy” at Maxim Group

Maxim Group upgraded shares of Moleculin Biotech (NASDAQ:MBRX) from a hold rating to a buy rating in a research report sent to investors on Tuesday morning,Benzinga reports. The brokerage currently has $4.00 price objective on the stock.

Several other equities analysts have also weighed in on MBRX. StockNews.com began coverage on shares of Moleculin Biotech in a report on Thursday, March 13th. They issued a “sell” rating on the stock. HC Wainwright reiterated a “buy” rating and issued a $8.00 price objective on shares of Moleculin Biotech in a report on Monday.

Moleculin Biotech Stock Performance

MBRX opened at $1.15 on Tuesday. Moleculin Biotech has a twelve month low of $0.40 and a twelve month high of $6.23. The firm’s 50-day moving average price is $1.33 and its 200 day moving average price is $2.00.

Moleculin Biotech Company Profile

Moleculin Biotech, Inc, a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs.